Researchers from Biohaven Pharmaceuticals Inc. presented preclinical data for the first-in-class extracellular bispecific IgG degrader, BHV-1300, being developed for the treatment of neuroinflammatory and autoimmune disease.
Hookipa Pharma Inc. has received clearance from the U.S. FDA for its IND application for HB-700, a novel arenaviral therapeutic vaccine for the treatment of KRAS-mutated cancers. The HB-700 program is a replicating 2-vector therapy designed to treat KRAS-mutated lung, colorectal, pancreatic and other cancers by targeting the five most prevalent KRAS mutations in these disease indications.
Shanghai De Novo Pharmatech Co. Ltd. has described antibody-immunostimulatory conjugates consisting of an antibody covalently bound to Toll-like receptor 8 (TLR8) agonists through a linker reported to be useful for the treatment of cancer.
Arbutus Biopharma Corp. has divulged programmed cell death protein 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of cancer, hepatitis B and hepatitis D infections.
Hanmi Holdings Co. Ltd. has identified serine/threonine-protein kinase/endoribonuclease IRE1 (ERN1) inhibitors described as potentially useful for the treatment of cancer.
Ariel Scientific Innovations Ltd. has synthesized microtubule destabilizers (tubulin polymerization inhibitors) reported to be useful for the treatment of cancer.
Multiple myeloma (MM) is still an uncurable disease. Chimeric antigen receptor (CAR) T cells directed to tumor necrosis factor receptor superfamily member 17, also known as BCMA, have transformed the field, with high response rate and durable remissions, but the access to this therapy is limited by multiple factors.
The FDA has cleared Oncoc4 Inc.’s IND application for ONC-841, a potential first-in-class Siglec-10-blocking antibody for the treatment of solid tumors.
RSS
